These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35460475)

  • 1. Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era.
    Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
    Target Oncol; 2022 May; 17(3):307-319. PubMed ID: 35460475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Apr; 51(5):793-801. PubMed ID: 33324983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study.
    Ishihara H; Nemoto Y; Nakamura K; Tachibana H; Ikeda T; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Kondo T; Takagi T
    Target Oncol; 2023 Mar; 18(2):209-220. PubMed ID: 36941516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
    Yanagisawa T; Mori K; Kawada T; Katayama S; Uchimoto T; Tsujino T; Nishimura K; Adachi T; Toyoda S; Nukaya T; Fukuokaya W; Urabe F; Murakami M; Yamanoi T; Bekku K; Komura K; Takahara K; Hashimoto T; Fujita K; Azuma H; Ohno Y; Shiroki R; Uemura H; Araki M; Kimura T;
    Urol Oncol; 2024 Nov; 42(11):374.e21-374.e29. PubMed ID: 39085019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
    Pignot G; Thiery-Vuillemin A; Albigès L; Walz J; Lang H; Balssa L; Parier B; Geoffrois L; Bensalah K; Schlürmann F; Ladoire S; Bigot P; Borchiellini D; Cassuto O; Thibault C; Ingels A; Saldana V; Roubaud G; Bernhard JC; Gravis G; Barthélémy P
    Eur Urol Oncol; 2022 Oct; 5(5):577-584. PubMed ID: 35853818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in the overall survival of patients with metastatic renal cell carcinoma in the era of immune-checkpoint inhibitors.
    Adhikari A; Sapkota S; Gogia S; Kc O
    Cancer Epidemiol; 2024 Oct; 92():102639. PubMed ID: 39146874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens.
    Saad E; Gebrael G; Semaan K; Eid M; Saliby RM; Labaki C; Sayegh N; Wells JC; Takemura K; Ernst MS; Lemelin A; Basappa NS; Wood LA; Powles T; Ernst DS; Lalani AA; Agarwal N; Xie W; Heng DYC; Choueiri TK
    Oncologist; 2024 Aug; 29(8):699-706. PubMed ID: 38630540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
    Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
    Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
    Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
    Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
    Urol Oncol; 2021 Jan; 39(1):77.e17-77.e25. PubMed ID: 32863124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.
    Dong H; Cao Y; Jian Y; Lei J; Zhou W; Yu X; Zhang X; Peng Z; Sun Z
    BMC Cancer; 2023 Oct; 23(1):943. PubMed ID: 37803307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions.
    Ishihara H; Fukuda H; Takagi T; Kondo T; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Ishida H; Tanabe K
    Int J Urol; 2021 Jan; 28(1):99-106. PubMed ID: 33159426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis.
    Tzeng A; Tzeng TH; Ornstein MC
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
    Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
    Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.
    Chahoud J; Msaouel P; Ross JA; McCormick BZ; Bathala TK; Gao J; Horn R; Xiao L; Sircar K; Campbell MT; Shah AY; Goswami S; Zurita AJ; Jonasch E; Matin SF; Wood CG; Karam JA; Sharma P; Tannir NM
    Urol Oncol; 2021 Feb; 39(2):134.e9-134.e16. PubMed ID: 33187886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.
    Naito S; Kato T; Numakura K; Hatakeyama S; Koguchi T; Kandori S; Kawasaki Y; Adachi H; Kato R; Narita S; Yamamoto H; Ogawa S; Kawamura S; Obara W; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N
    Int J Clin Oncol; 2021 Oct; 26(10):1947-1954. PubMed ID: 34191191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.